---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-001039"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2026-08-06T20:06:01+00:00"
generated_at: "2026-08-06T20:07:17.357514+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q2 net loss $23.8M; regains KOSTAIVE rights; ARCT-032 Phase 3 decision Q4 2026

## Summary
- Net loss of $23.8M ($0.84/share) vs $9.2M ($0.34/share) in Q2 2025; revenue fell to $3.0M from $28.3M due to CSL Seqirus termination.
- Regained global rights to KOSTAIVE and infectious disease portfolio from CSL Seqirus; received $12M cash and $16M in released liabilities.
- ARCT-032 (CF) Phase 2 enrollment on schedule; decision to proceed to Phase 3 expected Q4 2026; Thermo Fisher collaboration for Phase 3.
- ARCT-810 (OTC deficiency) Phase 2 enrollment and dosing completed; data and regulatory plan expected Q3 2026.
- Cash and cash equivalents $191.5M as of June 30, 2026; cash runway over 2.5 years through year end 2028.

## SEC filing metadata
- accession: 0001193805-26-001039
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2026-08-06T20:06:01+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/0001193805-26-001039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-001039
- JSON: https://secwatch.observer/filing/0001193805-26-001039.json
- Plain text: https://secwatch.observer/filing/0001193805-26-001039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.